Towards new tuberculosis vaccines

32Citations
Citations of this article
72Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

According to WHO, about one third of the world's population is infected with bacteria of the Mycobacterium tuberculosis complex. Currently there is globally 9.15 million recorded cases of overt tuberculosis (TB) annually and, due to lack of adequate diagnostics, presumably a large but unknown number of nonrecorded cases. TB is estimated to cause 1.65 million deaths per annum which accounts for one-fifth of all deaths by infectious diseases of adults in low-income countries. During recent years a rapid spread of multi-drug resistant bacteria causing about 0.5 million TB cases per year has worsened the problem. The live attenuated Bacillus Calmette-Guérin (BCG) vaccine which is the only currently available TB vaccine does not confer any significant protection against the most common and contagious form of TB - adult pulmonary TB. © 2010 Landes Bioscience.

Cite

CITATION STYLE

APA

Svenson, S., Källenius, G., Pawlowski, A., & Hamasur, B. (2010, April). Towards new tuberculosis vaccines. Human Vaccines. https://doi.org/10.4161/hv.6.4.10711

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free